ELEGANCENCT06930859
Non-interventional Study to Assess the Effectiveness and Safety of Ribociclib in the Adjuvant Therapy of Hormone Receptor Positive (HR+) HER2-negative Stage II and III Breast Cancer in Real Clinical Practice in Russia
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 12 versions: 12 with changes below. See every version on ClinicalTrials.gov ↗
- Notable Eligibility criteria expanded, about 17 words
- Trial sites expanded: 42 → 49 locations
- Secondary endpoints: details revised at 6 of 7 entries
- Minor Study sites: 40 to 42v11
- Minor Study sites: 39 to 40v10
- Minor Start date: Dec 22, 2025 to Dec 3, 2025v9
- Minor Study sites: 37 to 39v8
- Minor Trial sites expanded: 34 → 37 locationsv7
- Minor Study sites: 29 to 34v6
- Minor Study sites: 27 to 29
- Start date: Dec 3, 2025 to Dec 22, 2025
- Minor Study sites: 12 to 27v4
- Notable Trial status: Not Yet Recruiting to Recruiting
- Study sites: 2 to 12
- Start date changed from estimate of Dec 31, 2025 to Dec 3, 2025
- Notable Start date: Jul 31, 2025 to Dec 31, 2025
- Enrollment target: 2883 to 2766
- Study sites: 0 to 2
- Primary and study completion dates: Jul 31, 2032 to Dec 31, 2032
- Study First Submitted
- Notable: the plan changed
- Minor: routine updates
Endpoints
Primary
Invasive breast cancer-free survival (IBCFS) according to the Standardized Definitions for Efficacy End Points (STEEP) criteria in a prospective cohort
Timeframe: Months 36, 48, 60
Secondary (7)
Invasive breast cancer-free survival in prospective and retrospective cohorts depending on the tumor grade (G2/G3) and on the status of lymph nodes involvement (N0/N1/N2-3).
Invasive disease-free survival (IDFS) in prospective and retrospective cohorts depending on the tumor grade (G2/G3) and on the status of lymph nodes involvement (N0/N1/N2-3).
Recurrence-free survival (RFS) in the prospective and retrospective cohorts depending on the tumor grade (G2/G3) and on the status of lymph nodes involvement (N0/N1/N2-3).
Number of doses taken relative to the total planned doses of ribociclib %
Number of participants with AEs/SAEs including those of special interest, in patients receiving ribociclib
Show 2 moreShow less
Number of patients who discontinued ribociclib for any reason, due to any AE, and due to AEs of special interest
Patients' quality of life evaluated through a questionnaire
Arms and interventions
Ribociclib+AI
Patients with HR+ HER2- stage II-III breast cancer receiving adjuvant ribociclib plus AI (aromatase inhibitor)
Monotherapy AI
Patients with HR+ HER2- stage II-III breast cancer receiving adjuvant AI (aromatase inhibitor) monotherapy
Drugs: Ribociclib, Letrozole, Anastrozole
Sites
49 sites in 1 country